IL-15-armored CAR-T cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

The First Hospital of Jilin University1

Indications

Plasma Cell Leukemia (PCL)1
Relapsed/ Refractory Multiple Myeloma1
Cancer1

Other1 trial

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.